Leuprolide EP Impurity E represents a structurally related leuprolide derivative used to characterize degradation and synthetic by-products. Subtle modifications allow assessment of chromatographic resolution and analytical method robustness. Researchers employ it as a reference in impurity profiling and stability studies. Applications include process-development support, quality-control method validation, and peptide-chemistry investigation.
CAT No: Z10-101-195
Synonyms/Alias:(S)-N-Ethyl-1-(((S)-5-oxopyrrolidine-2-carbonyl)-L-histidyl-D-tryptophyl-L-seryl-L-tyrosyl-D-leucyl-L-leucyl-L-arginyl)pyrrolidine-2-carboxamide;L-Prolinamide,5-oxo-L-prolyl-L-histidyl-D-tryptophyl-L-seryl-L-tyrosyl-D-leucyl-L-leucyl-L-arginyl-N-ethyl;[3-D-Tryptophane]leuprorelin;D-[Trp]3-Leuprolide; (S)-1-((3S,6R,9S,12S,15R,18S,21S)-3-((1H-imidazol-5-yl)methyl)-6-((1H-indol-3-yl)methyl)-21-(3-guanidinopropyl)-12-(4-hydroxybenzyl)-9-(hydroxymethyl)-15,18-diisobutyl-1,4,7,10,13,16,19-heptaoxo-1-((S)-5-oxopyrrolidin-2-yl)-2,5,8,11,14,17,20-heptaazadocosan-22-oyl)-N-ethylpyrrolidine-2-carboxamide
Leuprolide EP Impurity E is a peptide-based reference compound structurally related to leuprolide, a well-characterized synthetic nonapeptide analog of gonadotropin-releasing hormone (GnRH). As an impurity standard, it represents a specific byproduct or degradation product that may arise during the synthesis, storage, or formulation of leuprolide. Its precise characterization and availability are essential for the comprehensive assessment of peptide drug quality, ensuring the reliability of analytical methods and supporting regulatory compliance in pharmaceutical development. The study of such impurities is integral to understanding peptide stability, degradation pathways, and the overall integrity of peptide-based therapeutics.
Analytical method development: Leuprolide EP Impurity E serves as a critical reference material in the development and validation of analytical techniques such as high-performance liquid chromatography (HPLC), mass spectrometry, and capillary electrophoresis. By providing a well-defined standard, it enables researchers and quality control laboratories to accurately identify, separate, and quantify this specific impurity within leuprolide formulations. This ensures the robustness and reproducibility of analytical protocols, facilitating precise impurity profiling and supporting batch release testing.
Pharmaceutical quality control: In the context of peptide drug manufacturing, the presence and quantification of related impurities are closely monitored to guarantee product consistency and safety. The availability of Leuprolide EP Impurity E allows for rigorous quality control processes, as it can be used to spike samples, calibrate instruments, and establish impurity thresholds. This is particularly important for meeting internal quality specifications and supporting comprehensive documentation required during regulatory submissions for peptide pharmaceuticals.
Degradation pathway elucidation: Understanding the chemical and enzymatic degradation of peptide drugs is vital for optimizing formulation strategies and predicting product shelf life. Leuprolide EP Impurity E is instrumental in mapping the degradation pathways of leuprolide by serving as a marker for specific transformation events. Its use in forced degradation studies and stability-indicating assays helps researchers pinpoint conditions that promote impurity formation, thereby informing the design of more stable peptide formulations.
Peptide synthesis optimization: The occurrence of impurities like Leuprolide EP Impurity E during solid-phase peptide synthesis or purification processes provides valuable feedback for process optimization. By tracking the formation and removal of this impurity, chemists can refine synthesis protocols, adjust reaction conditions, or improve purification steps to minimize unwanted byproducts. This contributes to higher yields of the target peptide and enhances overall process efficiency.
Reference standard for regulatory documentation: The use of well-characterized impurity standards is a cornerstone of regulatory submissions for peptide-based pharmaceuticals. Leuprolide EP Impurity E, when incorporated into impurity profiling studies, supports the generation of comprehensive impurity data packages required by health authorities. Its inclusion in method validation and stability testing documentation strengthens the scientific foundation of regulatory filings and facilitates the approval process for leuprolide drug products.
1. SERS spectrum of the peptide thymosin‐β4 obtained with Ag nanorod substrate
2. Immune-awakening Saccharomyces-inspired nanocarrier for oral target delivery to lymph and tumors
If you have any peptide synthesis requirement in mind, please do not hesitate to contact us at . We will endeavor to provide highly satisfying products and services.
Creative Peptides is a trusted CDMO partner specializing in high-quality peptide synthesis, conjugation, and manufacturing under strict cGMP compliance. With advanced technology platforms and a team of experienced scientists, we deliver tailored peptide solutions to support drug discovery, clinical development, and cosmetic innovation worldwide.
From custom peptide synthesis to complex peptide-drug conjugates, we provide flexible, end-to-end services designed to accelerate timelines and ensure regulatory excellence. Our commitment to quality, reliability, and innovation has made us a preferred partner across the pharmaceutical, biotechnology, and personal care industries.
Read More